Categories
CDE Diabetes

Practice Exam: Sexual Dysfunction and Hypogonadism in Men with Diabetes (Chapter 33)

Erectile dysfunction (ED) is a common and often overlooked complication that affects 35% to 90% of men with diabetes. Beyond quality of life, the 2018 Clinical Practice Guidelines identify ED as a critical marker for vascular health, potentially preceding coronary artery disease by several years.

This practice exam tests your ability to screen effectively, interpret diagnostic criteria for hypogonadism, and select safe pharmacological interventions based on cardiovascular comorbidities.

Key Concepts Covered in This Exam:

  • Vascular Warning Signs: Understanding that ED may be an early marker of underlying atherosclerosis and coronary artery disease, necessitating cardiovascular risk assessment.

  • Screening Recommendations: Identifying the requirement to screen all men with diabetes for ED using sexual function history or tools like the IIEF-5 questionnaire.

  • First-Line Therapy: Recognizing phosphodiesterase type 5 (PDE5) inhibitors as the first-line treatment for ED and understanding the absolute contraindication for their use in patients taking nitrates.

  • Hypogonadism Diagnosis: Mastering the diagnostic criteria for biochemical hypogonadism, which requires morning total testosterone measurement.

  • Testosterone Replacement: Knowing when testosterone replacement therapy is indicated—specifically for men with clinically significant symptoms and confirmed biochemical hypogonadism—and its potential benefits on insulin sensitivity.

1. Case: A patient with diabetes asks about the impact of intensive glycemic control on ED. Based on DCCT and UKPDS data, intensive glycemic control was effective for:

2.

Case: A 55-year-old man with type 2 diabetes reports difficulty achieving erections. What is the most appropriate first step in evaluation?

3. Case: A man with diabetes and diabetic retinopathy presents with ED. Based on the evidence linking diabetic complications and ED, what is the clinical significance of this association?

4. When should morning testosterone levels be drawn for biochemical testing of hypogonadism?

5. Case: A 52-year-old man with diabetes and ED does not respond to PDE5 inhibitors. What is the most appropriate next step according to guidelines?

6. What effect does significant weight reduction have on testosterone levels in hypogonadal men with diabetes?

7. What is the prevalence range of ejaculatory disorders in men with diabetes?

8.

Case: A 56-year-old man with type 2 diabetes, hypertension, and dyslipidemia presents with ED. When considering the relationship between ED and cardiovascular risk, what is the most appropriate clinical approach?

9.

The prevalence of hypogonadism in men with type 1 diabetes is:

10. Case: A 53-year-old man with ejaculatory dysfunction related to diabetes is interested in fertility. What is the most appropriate action?

11.

Case: A patient with ED asks about scheduled daily therapy with tadalafil versus on-demand dosing. What is an accurate statement about daily therapy?

12. What percentage of men with diabetes at 6 years after diagnosis have been reported to have ED?

13.

According to the guidelines, what is true regarding PDE5 inhibitor effectiveness in men with diabetes versus the general population?

14. What is the mechanism by which ED develops in men with diabetes related to the cGMP/NO pathway?

15. A patient with diabetes and hypogonadism asks about the conflicting evidence regarding testosterone therapy and cardiovascular outcomes. What is the most accurate statement based on current evidence?

16. Case: A 47-year-old man with type 2 diabetes reports fatigue, muscle weakness, and low libido. His morning testosterone is low. What other condition should be considered given his diabetes?

17. What is the approximate prevalence of erectile dysfunction (ED) in adult men with diabetes?

18. Case: A 44-year-old man with diabetes and ED asks about vacuum erection devices. In what clinical context have these been shown to be effective?

19. Which validated questionnaire can be used for assessing erectile function and measuring response to therapy?

20. Men with diabetes appear to have what characteristic regarding side effects from PDE5 inhibitors compared to the general population?

21. According to Diabetes Canada guidelines, when should screening for ED begin in men with type 2 diabetes?

22. When counselling a patient about the potential effects of testosterone therapy on glycemic control in type 2 diabetes, what should be explained based on current evidence?

23. What is the reported prevalence of hypogonadotropic hypogonadism in men with type 2 diabetes?

24. A 58-year-old man with diabetes has been symptomatic for hypogonadism. His total testosterone is 7.8 nmol/L (low) on two separate morning tests. In the absence of symptoms, would treatment be recommended?

25. What is the current mainstay of first-line therapy for erectile dysfunction in men with diabetes?

26. What percentage of newly diagnosed men with diabetes have been reported to have ED at presentation?

27.

What is the most significant predictor of hypogonadism in men with type 2 diabetes?

28.

Case: A healthcare team is developing a protocol for screening men with diabetes for sexual dysfunction. Based on guideline recommendations, which approach is most appropriate?

29. Case: A 60-year-old man with diabetes is considering testosterone therapy for hypogonadism. What monitoring is recommended prior to and during therapy?

30. Case: A 50-year-old man with diabetes and ED who does not respond to PDE5 inhibitors is found to have hypogonadism. What is the expected success rate when adding testosterone replacement?

31. Which type of ejaculatory disorder is most commonly associated with autonomic neuropathy in diabetes?

32. Case: A 50-year-old man with diabetes asks whether there is a specific testosterone preparation that is superior for treating hypogonadism. Based on current evidence, what is the most accurate response?

33. What is the rationale for the guideline recommendation that screening for symptomatic hypogonadism in men with type 2 diabetes is recommended rather than universal biochemical testing?

34. Case: A man with diabetes presents with ED. He has no cardiovascular symptoms but is concerned about CV risk. How is ED related to cardiovascular disease?

35. Case: A 48-year-old man with diabetes and ED is prescribed sildenafil. He is also taking medications for hypertension. Which medication is an absolute contraindication?

36. Case: A 45-year-old obese man with type 2 diabetes has symptoms of hypogonadism. Which of the following is a potentially reversible cause that should be addressed first?

37.

What percentage of men with diabetes report complete ED if they are greater than 60 years of age?

38. Considering the evidence linking hypogonadism and cardiovascular mortality in men with diabetes, what is the most clinically relevant statement?

39.

Case: A 42-year-old obese man with type 2 diabetes (BMI 38 kg/m²) has hypogonadism and ED. He asks whether weight loss might help both conditions. Based on evidence, what is the most appropriate counselling?

40. Why might measurement of bioavailable testosterone be helpful in some men with diabetes who have symptoms of hypogonadism but total testosterone in the lower normal range?


 

Categories
CDE Diabetes

Study Guide: Sexual Dysfunction and Hypogonadism in Men with Diabetes (Chapter 33)

1. Overview & Epidemiology

Sexual dysfunction is a common but often overlooked complication in men with diabetes. It significantly impacts quality of life and can serve as a “canary in the coal mine” for cardiovascular health.

  • Erectile Dysfunction (ED): Affects approximately 34% to 45% of adult men with diabetes.
    • Prevalence: Increases with age and duration of diabetes. Up to 50% of men have ED within 6 years of diagnosis.
    • CVD Link: ED may be an early clinical indication of cardiovascular disease (CVD). It is an independent marker for future cardiovascular events.
  • Hypogonadism (Low Testosterone):
    • Type 2 Diabetes: Highly prevalent (up to 40% of men).
    • Type 1 Diabetes: Prevalence is similar to the general population (not elevated).
    • Risk: Hypogonadism in men with diabetes is associated with higher cardiovascular mortality.

2. Screening Protocols

Because these issues are common and treatable, proactive screening is required.

  • Who to Screen for ED: All adult men with diabetes should be regularly screened.
  • How to Screen: A sexual function history is the primary tool. Validated questionnaires (like the IIEF or SHIM) can also be used.
  • When to Screen for Hypogonadism:
    • Screen men who are symptomatic (e.g., low libido, ED not responding to treatment, fatigue, muscle weakness).
    • Routine biochemical screening in asymptomatic men is not indicated.

3. Diagnosis of Hypogonadism (Testosterone Deficiency Syndrome)

Diagnosis requires careful timing due to natural hormonal fluctuations.

  • Test Timing: Measure Total Testosterone in the morning (between 7 am and 11 am or within 3 hours of waking).
  • Confirmation: If levels are low or borderline, repeat the test to confirm.
  • Bioavailable Testosterone: If Total Testosterone is borderline low-normal but symptoms are strong, measuring bioavailable testosterone is helpful (especially since SHBG is often low in insulin-resistant states, artificially lowering Total T).

4. Management of Erectile Dysfunction

A. First-Line Therapy: PDE5 Inhibitors

  • Agents: Sildenafil, Tadalafil, Vardenafil.
  • Efficacy: They are the mainstay of therapy and should be offered first-line.
  • Dosing: Can be “on-demand” or “daily” (scheduled).
  • Contraindications:
    • Nitrates: Absolute contraindication (risk of severe hypotension).
    • Unstable angina or untreated cardiac ischemia.

B. Second-Line & Adjunctive Therapies

  • Vacuum Constriction Devices: Useful for men who fail or cannot use PDE5 inhibitors.
  • Intracavernosal Injections: Prostaglandin E1 alone or in combination.
  • Referral: Men who do not respond to PDE5 inhibitors should be referred to a specialist.

5. Management of Hypogonadism

  • Weight Loss: In men with Type 2 diabetes and obesity, significant weight loss can increase testosterone levels, sometimes restoring eugonadism without medication.
  • Testosterone Replacement Therapy (TRT):
    • Considered for men who are symptomatic and biochemically hypogonadal.
    • Controversy: Evidence is conflicting regarding CV safety. Some studies suggest benefit, others potential risk. It is prudent to discuss this uncertainty with the patient.
    • Prostate Health: Monitor for prostate cancer before and during therapy (PSA, DRE).

6. Diabetes Canada 2018 Clinical Practice Guidelines Recommendations

Key takeaways from the “Recommendations” section (Page S231).

  1. Screening for ED: All adult men with diabetes should be regularly screened for ED with a sexual function history [Grade D, Consensus].
  2. First-Line ED Treatment: A PDE5 inhibitor should be offered as first-line therapy (on-demand or daily) [Grade A / Grade B].
  3. Investigating Non-Responders: Men with diabetes and ED who do not respond to PDE5 inhibitors should be investigated for hypogonadism (measure morning Total Testosterone) [Grade D, Level 4].
  4. Referral: Consider referral to a specialist for men who do not respond to or cannot take PDE5 inhibitors [Grade D, Consensus].
  5. Fertility: Men with ejaculatory dysfunction interested in fertility should be referred to a specialist [Grade D, Consensus].

 

Reference:

Bebb R, Millar A, Brock G. Sexual Dysfunction and Hypogonadism in Men With Diabetes. Canadian Journal of Diabetes. 2018;42:S228-S233. doi:10.1016/j.jcjd.2017.10.035
Categories
CDE Diabetes

Flashcards: Foot Care (Chapter 32)

Lower extremity complications are a leading cause of hospitalization and amputation in diabetes. These flashcards are designed to help pharmacists and healthcare professionals quickly recall the 2018 Clinical Practice Guidelines regarding risk stratification, the interprofessional approach to wound care, and the appropriate use of antimicrobials.

Key Topics Covered:

  • Risk Factors: Identifying peripheral neuropathy and peripheral arterial disease (PAD) as the primary drivers of foot ulceration and amputation.

  • Wound Management: Memorizing the core components of care: glycemic control, infection management, mechanical off-loading, and vascular assessment.

  • Antimicrobial Stewardship: Understanding the recommendation that antibiotics are not required for uninfected neuropathic ulcers and should be reserved for clinically infected wounds.

  • Dressing Selection: Recalling that there is insufficient evidence to support the routine use of expensive antimicrobial dressings over standard moist wound care.

  • Epidemiology: Recognizing the stark statistic that adults with diabetes are 20 times more likely to undergo nontraumatic lower limb amputation than the general population.

Categories
CDE Diabetes

Practice Exam: Foot Care (Chapter 32)

Lower extremity complications are a major cause of morbidity and mortality in people with diabetes. The 2018 Clinical Practice Guidelines emphasize that the treatment of foot ulcers requires a structured, interprofessional approach to address the underlying causes—such as neuropathy and peripheral arterial disease—and prevent the devastating outcome of amputation.

This practice exam tests your ability to apply the evidence-based recommendations for screening, wound management, and the appropriate use of antimicrobial therapy.

Key Concepts Covered in This Exam:

  • Risk Assessment: Recognizing that individuals with peripheral neuropathy and peripheral arterial disease are at the highest risk for developing foot ulcers and subsequent amputation.

  • Wound Management Principles: Understanding the interprofessional approach that includes glycemic control, infection management, mechanical off-loading of high-pressure areas, and assessment of vascular status.

  • Antimicrobial Stewardship: Identifying the recommendation that antibiotic therapy is not required for uninfected neuropathic foot ulcers and should be reserved for clinical infection.

  • Dressing Selection: Understanding the lack of sufficient evidence to support the routine use of proprietary antimicrobial dressings over standard moist wound care.

  • Amputation Prevention: Acknowledging that adults with diabetes are 20 times more likely to be hospitalized for nontraumatic lower limb amputation than those without diabetes, highlighting the urgency of effective care.

Please go to Practice Exam: Foot Care (Chapter 32) to view this quiz

Categories
CDE Diabetes

Study Guide: Foot Care (Chapter 32)

1. Overview & Epidemiology

Lower extremity complications are a major source of morbidity and mortality.

  • Amputation Risk: Adults with diabetes in Canada are 20 times more likely to undergo a non-traumatic lower limb amputation than those without diabetes.
  • Hospitalization: Foot ulcers are a leading cause of hospitalization for people with diabetes.
  • Recurrence: Individuals with a history of foot ulcers have a high rate of recurrence, making ongoing surveillance critical.

2. Risk Assessment

Every person with diabetes requires regular foot risk assessment.

  • Frequency: Perform a foot exam at least annually, and more frequently for high-risk individuals.
  • Key Risk Factors for Ulceration:

    • Peripheral Neuropathy (Loss of Protective Sensation).

    • Peripheral Arterial Disease (PAD).

    • Structural deformity (e.g., Charcot foot, hammer toes).

    • Previous ulcer or amputation.

    • Elevated A1C and Onychomycosis (fungal nail infection).

3. The Physical Exam (The "3-Minute Exam")

A proper foot exam includes three main components:

A. Neurological Assessment (Protective Sensation)

  • Tool: 10g Semmes-Weinstein Monofilament.

  • Method: Test specific sites on the plantar surface. Loss of sensation to the 10g monofilament is a significant independent predictor of future ulceration and amputation.

B. Vascular Assessment (Circulation)

  • Inspection: Look for skin color, hair growth, and temperature.

  • Palpation: Check dorsalis pedis and posterior tibial pulses.

  • Advanced Testing: Ankle-Brachial Index (ABI) is standard but may be falsely elevated (unreliable) in diabetes due to calcified arteries (medial arterial calcification). Toe Pressures (systolic toe pressure) are often more accurate in this population.

C. Dermatological/Musculoskeletal

  • Skin: Assess for calluses (pre-ulcerative lesion), fissures, blisters, or tinea pedis.

  • Structure: Look for deformities like Charcot arthropathy (collapsed arch, warmth, redness) or claw toes which increase pressure points.

4. Classification of Ulcers

Using a validated system helps predict outcomes. The guidelines highlight two systems:

  1. Wagner Classification: Grades 0 (intact skin) to 5 (gangrene of whole foot).
  2. University of Texas System: Incorporates Ischemia and Infection into the grading (Stages A, B, C, D), which improves prediction of amputation risk.

5. Management of Foot Ulcers

Treatment requires an interprofessional approach focusing on VIP: Vascular status, Infection, and Pressure off-loading.

  • Debridement: Regular debridement of non-viable tissue (callus/slough) is recommended to promote healing.
  • Infection:
    • Uninfected Ulcers: Do NOT use antibiotics (topical or systemic) for uninfected ulcers. It promotes resistance.
    • Infected Ulcers: Classify as mild (localized), moderate, or severe. Treat with empiric antibiotics covering Staph. aureus and Strep, then tailor based on deep tissue culture (swabs are unreliable).
  • Off-Loading (Pressure Relief):
    • Gold Standard: Total Contact Cast (TCC) or non-removable walker boot is the most effective method for healing plantar neuropathic ulcers.
    • Removable Cast Walkers: Effective if worn consistently (but compliance is lower).
  • Dressings: No single specific dressing type is superior. The principle is to maintain a physiologically moist wound environment.
  • Adjunctive Therapies: Therapies like negative pressure wound therapy (NPWT) or hyperbaric oxygen are not recommended for routine treatment of simple ulcers but may be considered for complex/non-healing wounds.

6. Charcot Neuroarthropathy

  • Definition: A progressive degeneration of a weight-bearing joint, characterized by bony destruction and deformity.

  • Acute Phase Signs: Red, hot, swollen foot (often mistaken for cellulitis).

  • Differentiation: If a foot is red/hot but the patient is afebrile and WBC is normal, suspect Charcot. Elevating the foot may decrease redness in Charcot (dependent rubor) but not in cellulitis.

  • Treatment: Immediate immobilization (Total Contact Cast) and non-weight bearing until the acute phase resolves (temperature normalizes).

7. Diabetes Canada 2018 Clinical Practice Guidelines Recommendations

Key takeaways from the “Recommendations” section (Page S226).

  1. Screening: Perform a foot exam at least annually to identify risk factors (neuropathy, PAD, deformity) [Grade C, Level 3].

  2. Education: High-risk individuals should receive foot care education and professionally fitted footwear [Grade D, Consensus].

  3. Prompt Treatment: Any foot ulcer or sign of infection requires prompt treatment by an interprofessional team [Grade C, Level 3].

  4. Wound Care:

    • Debride non-viable tissue [Grade A, Level 1A].

    • Use dressings that maintain a moist environment [Grade D, Consensus].

    • There is insufficient evidence to recommend specific dressing types or antimicrobial dressings for routine use [Grade C, Level 3].

  5. Adjunctive Therapy: Therapies like topical growth factors or dermal substitutes are not for routine use but may be considered for non-healing, non-ischemic wounds after standard care fails [Grade A, Level 1].

Reference:

Embil JM, Albalawi Z, Bowering K, Trepman E. Foot Care. Canadian Journal of Diabetes. 2018;42:S222-S227. doi:10.1016/j.jcjd.2017.10.020
Categories
CDE Diabetes

Flashcards: Neuropathy (Chapter 31)

Diabetic neuropathy affects up to 50% of people with diabetes within 10 years of diagnosis, significantly increasing the risk of foot ulcers, amputation, and cardiovascular mortality. These flashcards are designed to help pharmacists and healthcare professionals quickly recall the 2018 Clinical Practice Guidelines regarding screening techniques, preventive strategies, and the hierarchy of pharmacologic treatments for neuropathic pain.

Key Topics Covered:

  • Screening Tools: Memorizing the use of the 10 g Semmes-Weinstein monofilament and 128 Hz tuning fork for detecting loss of protective sensation.

  • Assessment Timelines: Recalling the different screening initiation protocols: starting at diagnosis for Type 2 diabetes versus 5 years post-diagnosis for Type 1 diabetes.

  • Pain Management: Identifying the first-line pharmacotherapies (anticonvulsants like pregabalin/gabapentin and antidepressants like duloxetine/venlafaxine) and understanding why opioids are not recommended as primary therapy.

  • Autonomic Neuropathy: Recognizing the clinical signs of autonomic dysfunction, such as resting tachycardia, orthostatic hypotension, and gastroparesis.

  • Differential Diagnosis: Understanding the importance of excluding other causes of neuropathy, such as Vitamin B12 deficiency (especially with metformin use) or alcohol overuse.

Categories
CDE Diabetes

Practice Exam: Neuropathy (Chapter 31)

Diabetic neuropathy is the most common complication of diabetes in North America, often developing within 10 years of diagnosis in up to 50% of patients. The 2018 Clinical Practice Guidelines stress that while there is no cure, the progression of neuropathy can be significantly delayed with early detection and optimal glycemic control.

This practice exam tests your ability to apply screening protocols, differentiate between peripheral and autonomic neuropathies, and select appropriate pharmacologic treatments for neuropathic pain.

Key Concepts Covered in This Exam:

  • Screening Protocols: Mastering the different screening timelines for Type 1 diabetes (starting 5 years post-diagnosis) versus Type 2 diabetes (at diagnosis) and the use of the 10 g monofilament or 128 Hz tuning fork.
  • Prevention Strategies: Understanding that intensive glycemic control is effective for preventing neuropathy in Type 1 diabetes and reducing its frequency in Type 2 diabetes.
  • Pain Management: Identifying evidence-based pharmacotherapies for painful diabetic neuropathy, including anticonvulsants (pregabalin, gabapentin) and antidepressants (duloxetine, venlafaxine), while recognizing that opioids are second-line or last-resort agents.
  • Autonomic Neuropathy: Recognizing the signs of cardiac autonomic neuropathy (CAN), gastroparesis, and erectile dysfunction, and the risks associated with them, such as resting tachycardia and postural hypotension.
  • Diagnostic Limitations: Knowing that simple screening tests like the monofilament are excellent for identification but that diagnosis requires excluding other causes (e.g., B12 deficiency, alcohol use).

Please go to Practice Exam: Neuropathy (Chapter 31) to view this quiz

Categories
CDE Diabetes

Study Guide: Neuropathy (Chapter 31)

1. Overview & Pathophysiology

Diabetic neuropathy is a heterogeneous group of disorders affecting the somatic and autonomic nervous systems. It is the most common complication of diabetes.

  • Distal Symmetric Polyneuropathy (DSPN): The most common form, typically presenting as a “stocking-glove” sensory loss or pain. It is a major risk factor for foot ulcers and amputation.

  • Risk Factors: The development of neuropathy is multifactorial. Key risk factors include:

    • Elevated blood glucose (A1C).

    • Elevated triglycerides.

    • High Body Mass Index (BMI).

    • Smoking.

    • Hypertension.

2. Screening Protocols

Screening is vital because the early stages of neuropathy are often asymptomatic (loss of sensation).

  • Frequency:

    • Type 1 Diabetes: Start 5 years post-diagnosis, then annually.

    • Type 2 Diabetes: Start at diagnosis, then annually.

  • Method (The “10g Monofilament”):

    • Screening should include testing with a 10g Semmes-Weinstein monofilament to detect Loss of Protective Sensation (LOPS).

    • Other assessments:

      • Vibration (128 Hz tuning fork).

      • Temperature.

      • Pinprick sensation.

      • Proprioception.

3. Management Strategies

Management is divided into prevention/slowing progression and symptom management.

A. Disease Modification (Glycemic Control)

  • Type 1 Diabetes: Intensive glycemic control significantly prevents or delays the development of neuropathy.

  • Type 2 Diabetes: Intensive control reduces the frequency of neuropathy but is less effective than in Type 1.

B. Management of Painful Neuropathy Neuropathic pain can be severe and debilitating (burning, shooting, lancinating). Treatment aims to reduce pain by ~30–50% and improve quality of life/sleep.

  • First-Line Pharmacotherapy:

    • Anticonvulsants: Pregabalin, Gabapentin.

    • Antidepressants (SNRI): Duloxetine, Venlafaxine.

    • Antidepressants (TCA): Amitriptyline, Nortriptyline (use with caution due to anticholinergic side effects).

  • Second-Line:

    • Opioid-like agents (e.g., Tramadol, Tapentadol) may be considered but have higher risk profiles.

5. Diabetes Canada 2018 Clinical Practice Guidelines Recommendations

Key takeaways from the “Recommendations” section (Page S220).

  1. Screening:

    • Type 1: Screen annually starting 5 years post-diagnosis [Grade D, Consensus].

    • Type 2: Screen annually starting at diagnosis [Grade D, Consensus].

  2. Tools: Use the 10g monofilament testing of the dorsal aspect of the great toe.

  3. Glycemic Control: Optimize control to prevent/delay neuropathy in Type 1 [Grade A, Level 1] and Type 2 [Grade B, Level 2].

  4. Pain Management:

    • Examples of agents: Pregabalin, Duloxetine, Gabapentin, Amitriptyline, Venlafaxine [Grade B, Level 2 for most].

    • Opioids (Tapentadol, Tramadol) are second-line [Grade B].

Reference:

Bril V, Breiner A, Perkins BA, Zochodne D. Neuropathy. Canadian Journal of Diabetes. 2018;42:S217-S221. doi:10.1016/j.jcjd.2017.10.028
Categories
CDE Diabetes

Flashcards: Retinopathy (Chapter 30)

Diabetic retinopathy remains the leading cause of new cases of blindness in working-age adults. These flashcards are designed to help pharmacists and healthcare professionals quickly recall the 2018 Clinical Practice Guidelines regarding screening intervals, the “ABC” prevention strategy, and the shift toward newer pharmacological treatments for preserving vision.

Key Topics Covered:

  • Screening Schedules: Memorizing the distinct initiation times for Type 1 diabetes (5 years post-diagnosis) versus Type 2 diabetes (at diagnosis) and follow-up frequencies.

  • Therapeutic Interventions: Identifying anti-VEGF (vascular endothelial growth factor) therapy as the first-line treatment for center-involved diabetic macular edema (DME).

  • The “ABCs” of Prevention: Recalling the role of optimal A1C, Blood pressure, and Cholesterol control—specifically the use of fenofibrate—in slowing disease progression.

  • Pregnancy Risks: Understanding why pregnancy confers a high risk for rapid retinopathy progression and the need for first-trimester screening.

  • Referral Criteria: Knowing when to refer to an ophthalmologist versus when optometric screening is sufficient.

Categories
CDE Diabetes

Practice Exam: Retinopathy (Chapter 30)

Diabetic retinopathy remains the leading cause of new cases of blindness in adults of working age. The 2018 Clinical Practice Guidelines emphasize that with optimal glycemic and blood pressure control, coupled with regular screening and timely treatment, the vast majority of vision loss can be prevented.

This practice exam tests your ability to apply specific screening schedules, recognize the risk factors for progression, and identify the appropriate therapeutic interventions for sight-threatening disease.

Key Concepts Covered in This Exam:

  • Screening Protocols: Mastering the different screening initiation times for Type 1 diabetes (5 years after diagnosis) versus Type 2 diabetes (at diagnosis) and the frequency of follow-up.

  • Risk Reduction: Understanding the evidence behind “ABC” management (A1C, Blood pressure, Cholesterol) and the specific role of fenofibrate in slowing retinopathy progression.

  • Therapeutic Interventions: Identifying anti-VEGF (vascular endothelial growth factor) therapy as the first-line treatment for center-involved diabetic macular edema (DME), replacing standard laser therapy for many patients.

  • Pregnancy Considerations: Recognizing the rapid progression of retinopathy that can occur during pregnancy and the requirement for more frequent ophthalmological assessments.

  • Referral Pathways: Knowing when to refer patients to an optometrist or ophthalmologist and how to interpret screening results to determine follow-up intervals.

Please go to Practice Exam: Retinopathy (Chapter 30) to view this quiz